Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID +2.19%34 Cash-to-Debt is 9.22 as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates OVID with a GF Score™ of 34/100 and a GF Value™ of $0.97 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,371 Biotechnology companies, Ovid Therapeutics ranks better than 53.98% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ovid Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 9.22.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ovid Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Ovid Therapeutics's Cash-to-Debt or its related term are showing as below:
OVID'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.86 Med: No Debt Max: No Debt
Current: 9.22
During the past 11 years, Ovid Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.86. And the median was No Debt.
OVID's Cash-to-Debt is ranked better than 53.98% of 1371
companies
in the Biotechnology industry
Industry Median: 6.78
vs OVID: 9.22
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ovid Therapeutics Cash-to-Debt Related Terms
Ovid Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Ovid Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (OVID) has a Cash-to-Debt of 9.22 as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Ovid Therapeutics' Cash-to-Debt has ranged from 1.86 to 10,000.00. According to the industry distribution chart, Ovid Therapeutics ranks #631 out of 1371 companies in the Biotechnology industry, placing it in the top 46%.
Is Ovid Therapeutics' Cash-to-Debt too high?
Ovid Therapeutics' current Cash-to-Debt of 9.22 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Ovid Therapeutics' value of 9.22 is 36% above this industry median. Based on the distribution chart, Ovid Therapeutics ranks #631 out of 1371 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Cash-to-Debt compare to SGMT and CABA?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #631 out of 1371 companies for Cash-to-Debt. This puts Ovid Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.78. Ovid Therapeutics' value of 9.22 is 36% above this benchmark. Historically, Ovid Therapeutics' own Cash-to-Debt has ranged from 1.86 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 6.78, Ovid Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,371 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovid Therapeutics's current Cash-to-Debt of 9.22 is 36% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current Cash-to-Debt is 9.22, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.97, compared to a current price of $2.80 — trading 188.1% above its estimated fair value. The current Cash-to-Debt is 9.22, which is 100% below median its 10-year median of 10,000.00 and 36% above the Biotechnology industry median of 6.78. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Cash-to-Debt is 9.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued.
The current stock price of $2.80 is trading 188.1% above its estimated GF Value™ of $0.97.
GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.
Key valuation signals for OVID:
Cash-to-Debt: 9.22 (100% below median its 10-year median of 10,000.00)
GF Value™: $0.97 vs. price of $2.80 (188.1% above fair value)
Industry Position: 36% above the Biotechnology median (#631 of 1371)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score
Get the complete analysis for OVID
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
